Although all-trans retinoic acid (ATRA) 
Introduction

Acute promyelocytic leukemia (APL) has become one of the most curable forms of leukemia by treatment with alltrans retinoic acid (ATRA) (1). ATRA can induce terminal differentiation and apoptosis of leukemia cells resulting in high rates of complete remission (CR)
. Although ATRA has been widely used, little data is available concerning patients with liver or renal dysfunction (3, 4) . Here, we report a Japanese APL patient with both liver and renal dysfunction, who achieved complete remission by ATRA; this case was also complicated with hypercalcemia during the treatment. In addition, we tried to assess the serum ATRA levels with reference to the clinical course. HD or non-HD day (3, 4) .
Discussion
One of the most characteristic features in the present case is that an APL patient, complicated by chronic renal failure and liver cirrhosis, can achieve molecular complete remission by full-dose ATRA treatment; this is the first such case because an appropriate dose of ATRA has not been previously suggested for such cases. ATRA, derivative of vitamin A, is known to be metabolized to produce 4-oxo ATRA, 4-oxo 13-cis retinoic acid, and many isomers by chromosome P-450-like enzyme in the liver, which is excreted as a glucuronide form in the bile (2/3) and urine (1/3) (6, 7). Whether ATRA will accumulate in such patients with liver and renal dysfunction is a matter of interest, as an accumulation of vitamin A in some patients with hemodialysis (HD) has been reported (8, 9); in addition, most of renal dysfunction in APL has been reported as a part of an ATRA syndrome or a thrombotic complication in disseminated intravascular coagulation (DIC), where organ dysfunctions might be temporal and could be overcome by induction of HD (10
As for liver function, ATRA has become one of the potential candidates for treatment of liver cirrhosis because it suppresses liver fibrosis through reduction of production of transforming growth factor β 1 (TGF β-1), interleukin 6, and type I collagen (11, 12 (15) . One of the limitations of bisphosphonate is that this may be influenced by renal dysfunction (15, 16) . However, the recent guideline describes there is no need to change the dosage in the use of pamidronate among patients with renal impairment (16) . Based on these findings, we were successfully able to administrate pamidronate without dose reduction of ATRA, but monitoring of renal function was necessary.
In conclusion, contrary to previous reports where ATRA is not recommended for patients with either liver or renal dysfunction, full dose ATRA therapy was applicable for an APL patient complicated by liver cirrhosis and renal failure not on hemodialysis. As dose reduction of ATRA is sometimes necessary in patients with renal failure (4, 17) , careful management is essential.
